Journal of Viral Hepatitis最新文献

{"title":"Epidemiological Burden of Hepatitis Delta Virus in the United States","authors":"Elizabeth M. Marlowe,&nbsp;Brooke E. Swanson,&nbsp;Susan E. Realegeno,&nbsp;William A. Meyer III,&nbsp;Robert Gish,&nbsp;Ron M. Kagan","doi":"10.1111/jvh.70029","DOIUrl":"https://doi.org/10.1111/jvh.70029","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis D virus (HDV) affects nearly 5% of people globally who are chronically infected with hepatitis B virus, according to the World Health Organisation. The prevalence of HDV in the United States is considered lower than in other countries. However, HDV seroprevalence studies of the US population are limited, and reported seroprevalences vary. To improve diagnoses, universal HDV testing of hepatitis B surface antigen (HBsAg)-positive specimens has been proposed. The objective of this study was to estimate the prevalence of HDV infection within the United States in HBsAg-positive specimens. Unique deidentified remnant HBsAg-positive specimens submitted for routine clinical testing to Quest Diagnostics, representing all 10 Health and Human Services (HHS) regions, were included. Reflex testing of HBsAg-positive specimens for HDV antibody testing, and further testing of positive specimens for HDV RNA, was conducted from July 2023 to June 2024 for 5251 HBsAg-positive specimens. The cohort was 45% female, with mean ages of 50.8 (M) and 49.4 (F) years. The seroprevalence of anti-HDV was 2.2% [95% CI: 1.8%–2.6%; range: 2.5%–4.1%]. Of 107 anti-HDV-positive specimens, 28% were positive for HDV RNA (viral load range: 94–7,480,000 IU/mL: <i>n</i> = 23; Detected &lt; 40 IU/mL: <i>n</i> = 7). This is the first nationwide seroprevalence study examining HBsAg-positive samples collected from 10 HHS regions across the United States, which offers an overview of the prevalence of HDV in the United States through the use of HbsAg-positive remnant specimens in proportion to regional population sizes. Expanded screening for HDV would help identify patients who may benefit from HDV-related interventions.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Government-Led, Patient-Centric Strategy to Re-Engage Diagnosed but Untreated Hepatitis C Patients in Yunnan Province, China","authors":"Shifu Li,&nbsp;Wenbin Dong,&nbsp;Yingni Yu,&nbsp;Zhibing Yang,&nbsp;Yang Luo,&nbsp;Ying Cai,&nbsp;Yongfen Zhu,&nbsp;Qiang Wu,&nbsp;Qiongfen Li,&nbsp;Shu Su,&nbsp;Rusong Yang","doi":"10.1111/jvh.70028","DOIUrl":"https://doi.org/10.1111/jvh.70028","url":null,"abstract":"<div>\u0000 \u0000 <p>Diagnosed but untreated (DBU) hepatitis C virus (HCV) infected patients are a key group for HCV elimination efforts. This study aims to pilot a government-led, multi-sectoral approach to universal patient recall and treatment mobilisation in Yunnan Province, China, to determine if this approach can improve treatment uptake among DBU patients and contribute to HCV elimination. In this quasi-experimental before-and-after study, we analysed all hepatitis C cases reported from 2004 to 2021 in the Yuxi City Center for Disease Control (CDC) database. From July to December 2022, the traditional telephone recall model was used, and from July 2023 to January 2024, Yuxi CDC partnered with local stakeholders to implement a patient-centric strategy to re-engage DBU patients in care. We compared the outcomes between these two approaches. The cooperation model significantly improved HCV case management. The contact rate rose from 29.7% (645/2171) to 58.5% (3813/6520) (<i>χ</i>^<i>2</i> = 25.743, <i>p</i> &lt; 0.001); the HCV-RNA testing rate increased from 18.9% (122/645) to 86.1% (3283/3813) (<i>χ</i>^<i>2</i> = 2760.164, <i>p</i> &lt; 0.001); and treatment initiation for positive cases improved from 19.6% (9/46) to 57.8% (884/1530) (<i>χ</i>^<i>2</i> = 26.555, <i>p</i> &lt; 0.001). In total, 936 patients received treatment, and 92 patients (9.8%) were lost to follow-up 12 weeks post-treatment. Of the remaining 844 patients, 841 (99.6%) achieved SVR12 (sustained virological response12 weeks after therapy, defined as HCV quantitative test below 15 IU/mL), with no significant difference in outcomes between tested and untested genotype groups (<i>χ</i>^<i>2</i> = 0.123, <i>p</i> = 0.725). This study highlights the substantial advantages of the cooperative model over the traditional approach, notably in contact, testing, and treatment rates, and successful SVR12 outcomes, underscoring the potential for such models in advancing HCV elimination.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Universal Screen-and-Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High-Endemicity City","authors":"Ngai Sze Wong,&nbsp;Denise Pui-Chung Chan,&nbsp;Grace Lai-Hung Wong,&nbsp;Shui Shan Lee","doi":"10.1111/jvh.70027","DOIUrl":"https://doi.org/10.1111/jvh.70027","url":null,"abstract":"<p>In the setting of high hepatitis B virus (HBV) endemicity, we studied the cost-effectiveness of universal HBV screen-and-treat strategies for averting HBV-related morbidity and mortality in Hong Kong, where diagnosis and treatment coverages are low. An age–sex-specific compartmental model for 2000–2040 was developed, with the incorporation of population-based screening strategies targeting different age groups. With a one-time HBV screening programme in 2025–2029, 3.6%–8.9% of HBV-related deaths could be averted. We evaluated the cost-effectiveness of the screening strategies with primary-care-based management in different scenarios with components of annual drug cost levels, screening programme duration, starting year and targeted age groups. Incremental cost-effectiveness ratio (ICER) was calculated, with the willingness-to-pay (WTP) threshold set at USD100,000/quality-adjusted life years (QALY). At the standard drug cost level, only the screening strategy targeting the 40–49 years old is cost-saving. When drug cost decreases to a low level, the strategy targeting the 35–49 years old (ICER USD97,042/QALY gained) is likely to be cost-effective and screening 35–59 years old is marginally cost-effective. In probabilistic sensitivity analysis, screening 40–49 years old (50%) and 35–59 years old (42%) have a half–half probability of being the most cost-effective at USD100,000/QALY WTP threshold, but increased to 93% for screening 35–59 years old at USD150,000/QALY threshold. From scenario analysis, deferred initiation of screening and unlimited programme duration would increase the ICER. Universal HBV screening targeting individuals aged 35–59 years or 40–49 years in the general population, with an earlier start and limited duration of the programme, is likely to be cost-effective.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 5","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143749687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden and Trends of Acute Hepatitis C From 1990 to 2021: An Analysis Based on the 2021 Global Burden of Disease Study","authors":"Xinwei Wang,&nbsp;Xipeng Yan,&nbsp;Baoren He,&nbsp;Bin Li,&nbsp;Linbin Huang,&nbsp;Jinlian Li,&nbsp;Rongji Lai,&nbsp;Mingshuang Lai,&nbsp;He Xie,&nbsp;Limin Chen","doi":"10.1111/jvh.70026","DOIUrl":"https://doi.org/10.1111/jvh.70026","url":null,"abstract":"<div>\u0000 \u0000 <p>Acute hepatitis C (AHC) represents a considerable challenge to global public health, although direct-acting antiviral (DAA) therapy has substantially improved therapeutic outcomes for hepatitis C virus infection. Data were exclusively obtained from the 2021 Global Burden of Disease (GBD) study, which examined trends in the burden of AHC in terms of incidence, mortality and disability-adjusted life years (DALYs) across 204 countries and territories globally from 2009 to 2021. In 2021, there were 7,009,910.02 incident cases, 5474.37 deaths and 266,087.98 DALYs due to AHC. Between 1990 and 2021, the number of incident cases increased by 24.61%, whereas mortality and DALYs cases decreased by 45.66% and 46.57%, respectively. The age-standardised incidence rate (ASIR), age-standardised mortality rate (ASMR) and age-standardised DALYs rate (ASDR) exhibited a declining trend. In 2021, the highest ASIRs of AHC were observed in Central Sub-Saharan Africa and Central Asia. At a national level, Mongolia and Egypt reported the highest ASIRs in 2021. The ASIR of AHC was similar in males and females, while females had higher ASMR and ASDR than males. The highest ASIR was observed in children under 5 years of age. Additionally, a negative association was found between the ASIR, ASMR, ASDR of AHC and sociodemographic index values at the regional and national levels. Our findings underscore the persistent severity of the global burden of AHC; effective and targeted strategies are needed to reduce the overall burden.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 5","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality","authors":"Annabel A. Powell,&nbsp;Annastella Costella,&nbsp;Rachel Roche,&nbsp;David Leeman,&nbsp;Ashley Brown,&nbsp;Beatrice Emmanouil,&nbsp;Mark Gillyon-Powell,&nbsp;Ross Harris,&nbsp;Holly D. Mitchell,&nbsp;Ruth Simmons,&nbsp;Monica Desai","doi":"10.1111/jvh.70016","DOIUrl":"https://doi.org/10.1111/jvh.70016","url":null,"abstract":"<p>The United Kingdom, along with many other countries, is working towards eliminating viral hepatitis as a public health threat by 2030, with a combined mortality target of less than or equal to six deaths per 100,000 population. The current methodology of reporting uses death registrations alone, which has been estimated to underestimate mortality rates by up to 60% for hepatitis C (HCV)-related liver disease. We aim to conduct a sensitivity analysis using data linkage of death certificates, hepatitis B (HBV) and HCV diagnoses and admissions for end-stage liver disease (ESLD) and/or hepatocellular carcinoma (HCC) to estimate mortality rates, assess progress towards elimination and evaluate underreporting. Between 2000 and 2023, 7967 deaths were reported due to HBV- and/or HCV-associated ESLD and/or HCC. Using data linkage of all three datasets, this increased to 11,487, with underreporting estimated to be 37% overall. The upper bound combined mortality rate was estimated to be 1.3 deaths per 100,000 population at its peak in 2015, therefore surpassing the WHO target for all years evaluated. From 2015 to 2023, both HCV-associated ESLD and/or HCC mortality decreased (1.12 to 0.88 deaths per 100,000 population), however, there was a slight increase for HBV-associated ESLD and/or HCC deaths during the same time frame (0.3 to 0.35). A higher proportion of HBV-related deaths were in males (<i>p</i> &lt; 0.05) who died outside London (<i>p</i> &lt; 0.05) and a lower proportion were White (<i>p</i> &lt; 0.05) when compared to HCV-related deaths. While England has met the WHO impact targets, it is important we continue to drive reductions in mortality.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hepatitis C Among Migrants: A Systematic Review and Meta-Analysis","authors":"Jiajun Sun,&nbsp;Matthew Kelly,&nbsp;Tsheten Tsheten,&nbsp;Davoud Pourmarzi","doi":"10.1111/jvh.70025","DOIUrl":"10.1111/jvh.70025","url":null,"abstract":"<p>The World Health Organisation has targeted the Hepatitis C virus (HCV) to be eliminated as a public health threat by 2030. Equitable access to HCV testing and treatment services is important in achieving this goal. Migrants often face barriers to accessing health services, and understanding HCV prevalence among this population can support planning for elimination. This systematic review aimed to estimate HCV prevalence among migrants residing in high-income countries with low/intermediate HCV prevalence. Scopus, PubMed, PsycINFO and Cochrane Library were searched for peer-reviewed articles published in English between 2015 and 2024. The studies' quality was assessed using The Joanna Briggs Institute (JBI) Critical Appraisal Tools. A proportional meta-analysis was used to estimate HCV prevalence. Thirty-seven studies were included in this review. Seventeen studies included both people &lt; 18 and ≥ 18 years old, 16 studies only included people ≥ 18 years old, and three studies included people aged 18 and younger. The pooled prevalence of HCV antibody (anti-HCV) and RNA (HCV-RNA) were 1.5% (95% CI, 1.1%–2.0%) and 0.6% (95% CI, 0.4%–0.9%), respectively. The prevalence of anti-HCV was higher among males (1.9%) than females (0.6%). Among refugees and asylum seekers, the prevalence of anti-HCV and HCV-RNA were 1.4% and 0.7%, respectively. The prevalence of HCV among migrants is comparable with that among the general population of the destination countries. Given the barriers migrants, especially refugees and asylum seekers, face in accessing health services, their access to HCV information, testing and treatment should be facilitated.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a High-Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection","authors":"Rex Wan-Hin Hui,&nbsp;Danny Ka-Ho Wong,&nbsp;Lung-Yi Mak,&nbsp;James Fung,&nbsp;Wai-Kay Seto,&nbsp;Man-Fung Yuen","doi":"10.1111/jvh.70023","DOIUrl":"https://doi.org/10.1111/jvh.70023","url":null,"abstract":"<p>Real-time polymerase chain reaction (PCR) is the current standard for serum HBV DNA measurement. However, conventional real-time PCR assays have technical limitations, and are not sensitive enough to detect low-level residual viremia in chronic hepatitis B (CHB) patients. We developed and validated a droplet digital PCR (ddPCR) assay for high-sensitivity detection of serum HBV DNA. A ddPCR assay was developed on the QX200 ddPCR System (Bio-Rad) for detection of serum HBV DNA in 200 μL of serum. The primers and probe were designed to target a highly-conserved region in the HBV X gene. The AcroMetrix HBV Panel (Thermo Fisher Scientific) and CHB patient samples were used for validation experiments to determine the assay sensitivity, specificity, linearity, intra-run variability, and inter-run variability. The ddPCR assay demonstrated lower limit of detection of 1.6 IU/mL and lower limit of quantification of 9.4 IU/mL for serum HBV DNA in probit regression. The assay also achieved excellent specificity (96.2%), linearity (<i>R</i> = 0.994, <i>R</i>²= 0.988, <i>p</i> &lt; 0.001), intra-run variability (mean coefficient of variation [CV]: 0.69%, average intra-run difference: 0.026 log IU/mL), and inter-run variability (mean coefficient of variation [CV]: 4.54%, average inter-run difference: 0.18 log IU/mL). To conclude, we developed a robust ddPCR assay that achieved higher detection sensitivity with lower serum input volume than conventional real-time PCR assays. Our assay may be utilised for measuring residual viremia after nucleos(t)ide analogue therapy or for monitoring patients on novel HBV antivirals.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B","authors":"Huiqing Liang,&nbsp;Xiaoting Zheng,&nbsp;Yaoyu Liu,&nbsp;Qianguo Mao,&nbsp;Chuncheng Wu,&nbsp;Li Lin,&nbsp;Zhizhen Huang,&nbsp;Yue Chen,&nbsp;Manying Zhang,&nbsp;Luyun Zhang,&nbsp;Jia Min,&nbsp;Min Hu,&nbsp;Huiying Luo,&nbsp;Shaodong Chen,&nbsp;Xiaohong Gu","doi":"10.1111/jvh.70019","DOIUrl":"https://doi.org/10.1111/jvh.70019","url":null,"abstract":"<div>\u0000 \u0000 <p>Oral nucleotide analogues (NAs) and peginterferon-α injections are commonly used for the treatment of patients with chronic hepatitis B (CHB). This study aims to evaluate the effects of different antiviral therapies on the degree of liver inflammation and fibrosis in CHB patients. This was a retrospective cohort study. A total of 101 CHB patients were admitted to the Liver Center of Xiamen Hospital of Traditional Chinese Medicine from 2017 to 2021 and were divided into three groups for different antiviral treatments: NAs therapy group (<i>n</i> = 36), peginterferon-α therapy group (<i>n</i> = 38) and nonantiviral therapy group (<i>n</i> = 27). The differences in degrees of liver inflammation and liver fibrosis between two histopathologic biopsies before and after treatment were analysed and compared to evaluate the efficacy of different treatments. The degrees of liver inflammation and liver fibrosis were improved after NAs or peginterferon-α therapy. In terms of improving the degree of liver inflammation, peginterferon-α therapy (74%) and NAs therapy (44%) were better than nonantiviral therapy (11%, <i>p</i> &lt; 0.05), although no significant difference was shown between peginterferon-α therapy and NAs therapy (<i>p</i> = 0.974). For liver fibrosis improvement, peginterferon-α therapy showed significantly better efficacy than NAs therapy (68% vs. 33%, <i>p</i> = 0.044), while NAs therapy was better than nonantiviral therapy (33% vs. 11%, <i>p</i> = 0.028). Peginterferon-α and NAs can significantly improve the degree of liver inflammation and liver fibrosis in CHB patients. Peginterferon-α is superior to NAs in delaying and reversing liver fibrosis. This study provides a new basis for peginterferon-α therapy to prevent progression of fibrosis in CHB patients.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection","authors":"Svenja Hardtke,&nbsp;Cihan Yurdaydin,&nbsp;Florin A. Caruntu,&nbsp;Manuela G. Curescu,&nbsp;Kendal Yalcin,&nbsp;Ulus S. Akarca,&nbsp;Selim Gürel,&nbsp;Stefan Zeuzem,&nbsp;Andreas Erhardt,&nbsp;Stefan Lüth,&nbsp;George V. Papatheodoridis,&nbsp;Kerstin Port,&nbsp;Michael P. Manns,&nbsp;Markus Cornberg,&nbsp;Julia Kahlhöfer,&nbsp;Heiner Wedemeyer","doi":"10.1111/jvh.70022","DOIUrl":"https://doi.org/10.1111/jvh.70022","url":null,"abstract":"<p>We analysed the frequency, severity and impact of hepatitis flares in a large Phase 2 study investigating pegylated interferon-alfa-2a (PEG-IFNa) for the treatment of hepatitis D. In the HIDIT-II study, 120 patients were treated for 96 weeks with PEG-IFNa (180 μg weekly) in combination with tenofovir disoproxil fumarate (TDF, 300 mg once daily) or placebo. Hepatitis flares were defined as ALT increases above 10 times the upper limit of normal or increases of more than 2.5-fold above baseline or nadir values. ALT flares occurred in 28 patients (23%) during treatment (&lt; 96) and in 14 patients post-treatment until follow-up Week 24. There were no differences in the flare frequency between the two treatment arms (12 PEG-IFNa + placebo vs. 16 PEG-IFNa + TDF). The frequency of ALT increases did not differ between cirrhotic and noncirrhotic patients. None of the patients with cirrhosis experienced liver decompensation during or after a flare. Fifty-four per cent of the patients with ALT flare experienced a decrease in HDV RNA (&gt; 1 log10 cop/ml) during subsequent study visits. Mean ALT levels early during treatment were higher in patients with HBsAg loss at follow-up Week 24. More than a third of hepatitis D patients undergoing PEG-IFNa therapy may experience ALT flares during or after treatment. ALT flares in this study posed no obvious safety risk to patients and should not lead to premature withdrawal from treatment. If ALT flares may be beneficial in single patients requires further investigation.</p><p>Clinical Trial Registration: NCT00932971, EudraCT 2008–005560-13.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of HBV Infection in Couples on In Vitro Fertilisation-Embryo Transfer Outcomes and Clinical Characteristics of Newborns: A Retrospective Study Based on 3900 Infertile Couples","authors":"Kaiwen Xue,&nbsp;Leji Wen,&nbsp;Xiaolei Ji,&nbsp;Xiaoyue Yan,&nbsp;Jiaqi Wen,&nbsp;Youzhu Li,&nbsp;Lei Zhang","doi":"10.1111/jvh.70015","DOIUrl":"https://doi.org/10.1111/jvh.70015","url":null,"abstract":"<div>\u0000 \u0000 <p>To investigate the effects of chronic HBV infection on the outcome of in vitro fertilisation-embryo transfer and clinical characteristics of newborns, as well as the factors influencing different outcomes of in vitro fertilisation-embryo transfer (IVF-ET). In this study, a total of 3900 couples undergoing IVF-ET were collected and divided into four groups according to the different HBsAg carrier status of each couple, comparing the general demographic data and clinical characteristics between the four groups, analysing the differences in IVF-ET outcomes between the groups, and using multifactorial analysis of factors influencing their IVF-ET outcomes. The results showed that no significant differences (<i>p</i> &gt; 0.05) were found in IVF-ET outcomes among the four groups, but multifactorial logistic regression showed that male and female age, low literacy level of men, total number of eggs acquired, LH value and P value on HCG day may affect the success rate of different IVF-ET outcomes (embryo outcome, pregnancy outcome and perinatal outcome) to different degrees. We also analysed the clinical data of 952 newborns and there were no statistically significant differences (<i>p</i> &gt; 0.05) in variables including sex distribution, length, weight, health status and Apgar score. Therefore, our study suggests that neither uniparental infection nor biparental HBV infection may affect the outcome of IVF-ET or the clinical characteristics of the newborns, but the outcome of IVF-ET is affected by different factors.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 4","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}